Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy TherapeuticsMD stock | 1.23

Own TherapeuticsMD stock in just a few minutes.


Fact checked

TherapeuticsMD, Inc is a drug manufacturers—specialty & generic business based in the US. TherapeuticsMD shares (TXMD) are listed on the NASDAQ and all prices are listed in US Dollars. TherapeuticsMD employs 348 staff and has a trailing 12-month revenue of around USD$58.2 million.

How to buy shares in TherapeuticsMD

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for TherapeuticsMD. Find the stock by name or ticker symbol: TXMD. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until TherapeuticsMD reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$1.23, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of TherapeuticsMD, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of TherapeuticsMD. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted TherapeuticsMD's share price?

Since the stock market crash in March caused by coronavirus, TherapeuticsMD's share price has had significant negative movement.

Its last market close was USD$1.23, which is 40.29% down on its pre-crash value of USD$2.06 and 36.88% up on the lowest point reached during the March crash when the shares fell as low as USD$0.8986.

If you had bought USD$1,000 worth of TherapeuticsMD shares at the start of February 2020, those shares would have been worth USD$432.42 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$545.46.

TherapeuticsMD share price

Use our graph to track the performance of TXMD stocks over time.

TherapeuticsMD shares at a glance

Information last updated 2020-11-24.
Latest market close USD$1.23
52-week range USD$0.853 - USD$2.93
50-day moving average USD$1.44
200-day moving average USD$1.4559
Wall St. target price USD$6.9
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-0.715

Buy TherapeuticsMD shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Stocks, Mutual funds, ETFs, Forex
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
or $25 broker-assisted
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy TherapeuticsMD stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

TherapeuticsMD price performance over time

Historical closes compared with the close of $1.23 from 2020-11-16

1 week (2020-11-20) N/A
1 month (2020-10-30) 0.82%
3 months (2020-08-28) N/A
6 months (2020-05-28) N/A
1 year (2019-11-27) N/A
2 years (2018-11-27) N/A
3 years (2017-11-27) N/A
5 years (2015-11-27) N/A

TherapeuticsMD financials

Revenue TTM USD$58.2 million
Gross profit TTM USD$43.3 million
Return on assets TTM -48.37%
Return on equity TTM 0%
Profit margin 0%
Book value $0.034
Market capitalisation USD$397 million

TTM: trailing 12 months

Shorting TherapeuticsMD shares

There are currently 83.3 million TherapeuticsMD shares held short by investors – that's known as TherapeuticsMD's "short interest". This figure is 2% down from 85.0 million last month.

There are a few different ways that this level of interest in shorting TherapeuticsMD shares can be evaluated.

TherapeuticsMD's "short interest ratio" (SIR)

TherapeuticsMD's "short interest ratio" (SIR) is the quantity of TherapeuticsMD shares currently shorted divided by the average quantity of TherapeuticsMD shares traded daily (recently around 2.3 million). TherapeuticsMD's SIR currently stands at 35.61. In other words for every 100,000 TherapeuticsMD shares traded daily on the market, roughly 35610 shares are currently held short.

However TherapeuticsMD's short interest can also be evaluated against the total number of TherapeuticsMD shares, or, against the total number of tradable TherapeuticsMD shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case TherapeuticsMD's short interest could be expressed as 0.31% of the outstanding shares (for every 100,000 TherapeuticsMD shares in existence, roughly 310 shares are currently held short) or 0.3385% of the tradable shares (for every 100,000 tradable TherapeuticsMD shares, roughly 339 shares are currently held short).

A SIR above 20% would generally be considered very high, pointing to a pessimistic outlook for the share price, with a discouraging number of investors currently willing to bet against TherapeuticsMD.

Find out more about how you can short TherapeuticsMD stock.

TherapeuticsMD share dividends

We're not expecting TherapeuticsMD to pay a dividend over the next 12 months.

Have TherapeuticsMD's shares ever split?

TherapeuticsMD's shares were split on a 1:100 basis on 3 October 2011. So if you had owned 100 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your TherapeuticsMD shares – just the quantity. However, indirectly, the new 9900% higher share price could have impacted the market appetite for TherapeuticsMD shares which in turn could have impacted TherapeuticsMD's share price.

TherapeuticsMD share price volatility

Over the last 12 months, TherapeuticsMD's shares have ranged in value from as little as $0.853 up to $2.93. A popular way to gauge a stock's volatility is its "beta".

TXMD.US volatility(beta: 2.2)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while TherapeuticsMD's is 2.1984. This would suggest that TherapeuticsMD's shares are significantly more volatile than the average for this exchange and represent a higher risk.

TherapeuticsMD overview

TherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; and TX-00THR and TX-0008HR, which are transdermal patch product candidates. The company's clinical development product is TX-009HR, an oral progesterone and estradiol formulation. It also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands. The company sells its prescription prenatal vitamin and hormone therapy drug products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. is headquartered in Boca Raton, Florida.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site